<p>Bayer AG announced positive topline results from the global Phase III OCEANIC-STROKE study of asundexian, an oral once-daily FXIa inhibitor, for secondary prevention of stroke. The study met its primary efficacy and safety endpoints. Asundexian is currently under investigation as a potential treatment for thrombosis prevention and has not yet been approved by any health authority. The results were announced on November 23, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2234580_de), on November 23, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

BAYZF

BAYRY

<p>Bayer AG announced positive Phase III results for asundexian in the OCEANIC-STROKE study, meeting primary efficacy and safety endpoints for stroke prevention. Asundexian is under investigation for thrombosis prevention and is not yet approved by health authorities. The announcement was made on November 23, 2025.</p>

Bayer Reports Positive Phase III Results for Asundexian in Stroke Prevention Trial